TARDBP and amyotrophic lateral sclerosis: In addition, RACK1 KD led to a reduction of low molecular weight fragments and phosphorylated-TDP-43 in the cytoplasm by ~ 50% and ~ 21%, respectively (Fig. 7d), which are both hallmark biochemical features of TDP-43 pathology in affected CNS regions of ALS/FTLD patients [3, 11, 15, 44, 55, 63, 67].